Obraztsova O A, Verbenko D A, Karamova A E, Semenova V G, Kubanov A A, Deryabin D G
FGBU "State Scientific Center of Dermatovenereology and Cosmetology" Ministry of Health of Russia, 107076, Moscow, Russia.
Klin Lab Diagn. 2018;63(8):511-516. doi: 10.18821/0869-2084-2018-63-8-511-516.
Certain level of new registered cases of leprosy in a number of endemic countries in the world, as well as growing rate of transboundary migratory flows, raise the issue of effective diagnosis of this disease in countries with sporadic incidence of leprosy, including the Russian Federation. The purpose of the study was to develop a highly sensitive PCR test for detecting the genetic material of Mycobacterium leprae and to compare the test robustness and sensitivity with the commercially available Leprosy Genesig Standard Kit (Primerdesign Ltd., UK). The proposed approach uses real time PCR of non-coding repeating element RLEP, unique for the M. leprae genome, using TaqMan probe. The high test specificity was shown using the reference DNA samples of pathogenic and conditionally pathogenic mycobacterium, as well and its comparison with single-copy genes of M. leprae (rrs, fbp, MntH) PCR detection. The use of a commercially available test system based on the single-copy rpoB gene detection provided 59.4% sensitivity to the detection of M. leprae in the clinical material, while the application of the developed approach increased this index to 96.8%. The developed PCR diagnostics test of leprosy is submitted for state clinical approval process, whereupon the practical use of the test diagnostics allows solving a wide range of tasks to identify and confirm new cases of leprosy, and monitoring both the effectiveness of leprosy treatment, and epidemiological (including transboundary) the spread of the disease.
世界上一些麻风病流行国家的麻风病新登记病例达到一定水平,以及跨境移民流动率不断上升,这引发了在包括俄罗斯联邦在内的麻风病散发国家有效诊断该疾病的问题。本研究的目的是开发一种用于检测麻风分枝杆菌遗传物质的高灵敏度聚合酶链反应(PCR)检测方法,并将该检测方法的稳健性和灵敏度与市售的麻风病基因检测标准试剂盒(英国Primerdesign有限公司)进行比较。所提出的方法使用针对麻风分枝杆菌基因组独特的非编码重复元件RLEP进行实时PCR,采用TaqMan探针。使用致病性和条件致病性分枝杆菌的参考DNA样本,以及将其与麻风分枝杆菌单拷贝基因(rrs、fbp、MntH)的PCR检测进行比较,显示出该检测具有高特异性。基于单拷贝rpoB基因检测的市售检测系统对临床材料中麻风分枝杆菌检测的灵敏度为59.4%,而应用所开发的方法可将该指标提高到96.8%。所开发的麻风病PCR诊断检测方法已提交国家临床审批程序,一旦该检测诊断方法实际投入使用,便能够解决一系列任务,以识别和确认麻风病新病例,并监测麻风病治疗效果以及该疾病的流行病学(包括跨境)传播情况。